However, no increased risk of perianal or stricturing complications has been observed in CD patients (86, 87)
In a long-term evaluation of the LEADER trial with 9,340 patients with T2D over a 3.5- to 5-year period, there was no evidence of C-cell malignancies occurred in the liraglutide group [84]
That compares with a discontinuation rate of 11.3% among patients who took the highest dose
There are two main reasons people use compounding pharmacies
The trials used different designs, timelines, and participants, so TRIUMPH-5 is the study that can settle the direct comparison
Warmer temperatures can speed up bacterial growth, especially if the medication has been left out for a prolonged time